Pfizer Inc.· @pfizer · X·· 2026-06-26AI 评分40
AI 导读
VESPER-6 和 SOLIS-1 已完成首例受试者给药，这是辉瑞 2026 年肥胖管线计划启动的 20 多项研究的一部分。 了解更多管线信息：http://pfizer.com/pipeline
正文
The first participants have been dosed in VESPER-6 and SOLIS-1, part of 20+ study starts planned across Pfizer's obesity pipeline in 2026.
Learn more about our pipeline: http://pfizer.com/pipeline
We dosed the first participants in VESPER-6, the latest Phase 3 trial of our lead investigational medicine in obesity and started a Phase 2b study testing it in combination with an investigational amylin analog.在 X 查看被引用的帖子
来源：Pfizer Inc. · x.com